0.8199
price down icon26.79%   -0.3001
pre-market  Pre-market:  .74   -0.0799   -9.75%
loading
Promis Neurosciences Inc stock is traded at $0.8199, with a volume of 14.49M. It is down -26.79% in the last 24 hours and up +63.98% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$1.12
Open:
$1.02
24h Volume:
14.49M
Relative Volume:
2.34
Market Cap:
$26.80M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-4.1077
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
+86.34%
1M Performance:
+63.98%
6M Performance:
-12.16%
1Y Performance:
-57.52%
1-Day Range:
Value
$0.77
$1.03
1-Week Range:
Value
$0.4011
$1.59
52-Week Range:
Value
$0.38
$2.1168

Promis Neurosciences Inc Stock (PMN) Company Profile

Name
Name
Promis Neurosciences Inc
Name
Phone
416-847-6898
Name
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
PMN's Discussions on Twitter

Compare PMN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PMN
Promis Neurosciences Inc
0.8199 14.38M 0 -563.30K -22.23M -0.1996
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Promis Neurosciences Inc Stock (PMN) Latest News

pulisher
12:09 PM

Is ProMIS Neurosciences Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com

12:09 PM
pulisher
Jul 22, 2025

Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize

Jul 22, 2025
pulisher
Jul 22, 2025

Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede - Cantech Letter

Jul 22, 2025
pulisher
Jul 22, 2025

Alzheimer’s stock triples after FDA Fast-Track Designation - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Plunges 24.56% Intraday—Is the FDA Fast Track Outpacing Investor Sentiment? - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Plunges 30.5% Intraday—What Storm Clouds Loom Over a Biotech Betting on Alzheimer’s Innovation? - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

What makes ProMIS Neurosciences Inc. stock price move sharplyBreakout Level Watch - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences announces $0.8M registered direct offering - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences announces private placement financing - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences stock gets FDA Fast Track designation for PMN310 - Investing.com

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences (PMN) Secures Funding to Enhance Therapeuti - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

What drives ProMIS Neurosciences Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310 - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Drops 9.82% Amid ICICI Bank's Strong Earnings - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Gains FDA Fast Track for PMN310 - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Alzheimer's Treatment Pioneer ProMIS Secures New Funding to Accelerate PMN310 Clinical Trials - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

3 Penny Stocks to Watch Now, 7/22/25 - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about ProMIS Neurosciences Inc. stockExceptional return forecasts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences: Stock Surge Insight - StocksToTrade

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Soars 157% on FDA Fast Track Designation – What’s Fueling This Volatile Rally? - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Surges: Analyzing Recent Moves - timothysykes.com

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Why ProMIS Is Rising In Pre-market? - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences granted Fast Track designation by FDA for PMN310 - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Granted Fast Track Designation by U.S. - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

FDA Fast-Tracks Revolutionary Alzheimer's Drug Promising Fewer Side Effects Than Current Treatments - Stock Titan

Jul 21, 2025

Promis Neurosciences Inc Stock (PMN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Cap:     |  Volume (24h):